The Form 4 filing, an SEC report of insider stock transactions, was submitted on Nov. 19, 2026. The purchase took place on Nov. 17, two days before the filing date. It lists Broadwood Partners, L.P. as a director and 10% owner of Lineage Cell Therapeutics (LCTX).
The company is listed in the healthcare sector and biotechnology industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-17 |
| Date of Latest Transaction | 2026-11-17 |
| Buy/Sell | buy |
| Transaction Count | 1 |
| Shares Transacted | 1,000,000 |
| Price | $0.77 |
| Total Transaction Value | $770,700.00 |
| Insider | |
| Ticker Symbol | LCTX |
| Company | Lineage Cell Therapeutics, Inc. |
| Insider Name | BROADWOOD PARTNERS, L.P. |
| Insider Title | Director, 10% Owner |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 50,560,992 |
| Position Size Change | 1.98% |
| Filing | |
| Filing Date | 2026-11-19 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a purchase of company shares, marked with transaction code P. Broadwood Partners, L.P. bought 1,000,000 LCTX shares in one transaction dated Nov. 17, 2026.
What was the average price of the transaction?
The average price was $0.7707 per share, or just over 77 cents. The transaction table shows this as $0.77 after rounding to two decimal places.
How did this transaction affect the insider's holdings?
After buying 1,000,000 shares, Broadwood Partners, L.P. reported owning 50,560,992 shares. The purchase made up 1.98% of the shares it owned after the trade.
What's the total transaction value?
The total transaction value was $770,700.00 for the one reported purchase. This covers 1,000,000 shares bought at an average price of $0.7707 each.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement for this purchase. Filing footnotes were not provided, so any further terms or explanations remain unknown.
For research purposes only; not investment advice.